Using patient-reported data to estimate costs associated with melanoma in the UK: a digital registry

Page 1

Using patient-reported data to estimate costs associated with melanoma in the UK: a digital registry Mishal Javed¹, Casey Quinn², Fatemeh Amini², Emily Boxell² ¹The Ministry of National Health Services, Regulations and Coordination, Islamabad, Pakistan ²Vitaccess Ltd, Oxford, UK

Background Malignant melanoma is the fifth most prevalent cancer in the UK, and one of the leading cancers with regard to average years of life lost per death from disease¹. Despite this, there is a lack of data describing costs associated with melanoma for patients and the National Health Service (NHS).

Additional sources were used, such as UK National Institute for Health and Care Excellence (NICE) technology appraisals, for unit costs and in cases of limited data availability. A combination of top-down and bottom-up methods were applied to calculate costs for various domains of the disease pathway, including: ●

Routine monitoring and management of disease

Objective

Drugs and administration

To estimate costs to the UK health system for the complete disease pathway in melanoma using real-world patient-reported data.

Management of treatment-related adverse events

Methods Data were principally from the Melanoma UK digital registry, an observational study collecting patient-reported real-world evidence on the impact of melanoma and its management through the My Melanoma study app (Vitaccess Ltd).

Calculations were used to provide a snapshot of costs in the UK in 2019.

Results Taking into account several simplifying assumptions, the total costs associated with melanoma – calculated using data from 134 participants in the My Melanoma study – were estimated at:

£43,944 per patient

Figure 1: My Melanoma study

Countries takign part in study from 12th August 2019

Countries takign part in study from 12th August 2019

2005 France United kingdom Switzerland Ireland Spain United States Italy Denmark

United kingdom Switzerland Ireland United States Italy Denmark

£5.3 billion for the whole UK population

Of all domains, drug therapies were found to be the costliest, with approximately 79% of the total costs attributed to this domain alone.

Year of birth

2000 1995 1990 1985 1980 1975 1970 1965 1960

Table 2: Other costs

Discussion & Conclusions This analysis produced a detailed, bottom-up picture of the perpatient costs to the UK health system of managing melanoma. To our knowledge, costing of the entire disease pathway in melanoma has not previously been attempted, nor costing at the level of the patient’s journey. These data and results should be considered a starting point: the entire patient journey is not fully captured, and much additional specificity can be developed with more data over time.

1955 1950

Symptoms showing after current medication

1945

Symptoms showing after current medication

Tiredness Numbness Sickness Swelling Hearing Hospitalisation

Tiredness Numbness Swelling Hearing Hospitalisation

Red

Brown

Yellow

Blue

Green

Red

Brown

Yellow

Blue

Green

Year of birth

2005 2000 1995 1990 1985 1980

Symptoms showing after any/all medication

1975

Symptoms showing after any/all medication

1970 1965 1960 1955 1950

Speech Sight Hearing

1945 Speech Sight

Year of birth

Table 1: Costliest resource within different domains

References

2005

¹Cancer Research UK. Melanoma skin cancer statistics. Available at: https://www.cancerresearchuk.org/health-professional/ cancer-statistics/statistics-by-cancer-type/melanoma-skin-cancer#heading-Zero. Accessed: December 2020.

Adult participants, diagnosed with melanoma & living in the UK

Demographic & patientreported outcome (PRO) data collected regularly on the My Melanoma study app

Real-world data made accessible to researchers on realtime interactive dashboards

Get in touch at www.vitaccess.com | National PROMs Annual Conference 2022


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.
Using patient-reported data to estimate costs associated with melanoma in the UK: a digital registry by VITACCESS - Issuu